iQure Pharma

Company snapshot

iQure is a clinical-stage biotech company advancing a new therapeutic approach for CNS disorders by restoring glutamate homeostasis. Our science targets one of the core functions of astrocytes: the regulation of glutamate uptake, essential for maintaining synaptic balance and protecting neurons from overstimulation. By enhancing the function of the main transporter involved in this process, we bre

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for iQure Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for iQure Pharma.

1. Jun 8, 2026 Clinical update

   CT-AMT-130-02 — Phase 2

2. Jun 8, 2026 Clinical update

   AMT-162-001 — Phase 2

View all clinical trial activity →

• What is iQure Pharma?

  uniQure biopharma is a biotech organization headquartered in EU. Primary therapeutic focus areas include Huntington’s Disease, Amyotrophic Lateral Sclerosis (ALS). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA

• Is iQure Pharma publicly traded?

  iQure Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does iQure Pharma develop or market?

  We link 2 drug profile(s) where iQure Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/uniqure-biopharma-b-v#company-drugs.

• What are the latest developments for iQure Pharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does iQure Pharma focus on?

  iQure Pharma focuses on Huntington’s Disease, Amyotrophic Lateral Sclerosis (ALS) based on our analysis of their pipeline programs and drug development activities.